The rise of Sildenafil initially fueled a period of growth for major pharmaceutical companies, however recent changes present a complicated picture for those considering a stake. Generic versions are eroding earnings, and ongoing patent challenges add additional complexity to the situation. While some companies might still gain from related serv… Read More